MCID: KHN001
MIFTS: 47

Kuhnt-Junius Degeneration

Categories: Eye diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 11 14
Neovascular Age-Related Macular Degeneration 11 14
Exudative Senile Macular Degeneration of Retina 11
Exudative Age-Related Macular Degeneration 71
Wet Senile Macular Retinal Degeneration 11
Senile Macular Degeneration, Wet 11
Exudative Macular Degeneration 71

Classifications:



External Ids:

Disease Ontology 11 DOID:10873
ICD9CM 34 362.52
SNOMED-CT 68 11290001
UMLS 71 C0271084 C2237660

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary: Kuhnt-Junius Degeneration, also known as neovascular age-related macular degeneration, is related to retinal detachment and microvascular complications of diabetes 5. An important gene associated with Kuhnt-Junius Degeneration is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Nepafenac and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 284)
# Related Disease Score Top Affiliating Genes
1 retinal detachment 31.5 VEGFA COL18A1 CFH ARMS2
2 microvascular complications of diabetes 5 31.4 VEGFA TEK PLG PGF KDR FLT1
3 vitreous detachment 31.3 VEGFA RPE65 PLG PGF
4 retinal vein occlusion 31.3 VEGFA KDR ANGPT2
5 endophthalmitis 31.2 VEGFB VEGFA RPE65 PLG PGF FLT1
6 central serous chorioretinopathy 31.2 VEGFA CFH ARMS2
7 macular retinal edema 31.2 VEGFB VEGFA TEK RPE65 PGF KDR
8 retinal disease 31.1 VEGFA RPE65 CRYAA CFHR2 CFH ARMS2
9 microvascular complications of diabetes 1 31.0 VEGFA FLT1 ANGPT2
10 macular holes 30.9 VEGFA RPE65 PLG CRYAA ANGPT2
11 angioid streaks 30.8 VEGFA PGF CFH ARMS2
12 vitreoretinopathy, neovascular inflammatory 30.8 VEGFA RPE65 CRYAA
13 hypertensive retinopathy 30.7 VEGFA CFH
14 severe nonproliferative diabetic retinopathy 30.7 VEGFB VEGFA PGF
15 basal laminar drusen 30.7 CFH CFB ARMS2
16 complement component 2 deficiency 30.7 CFH CFB ARMS2
17 refractive error 30.6 VEGFA RPE65 CRYAA CFH ARMS2
18 retinal perforation 30.6 VEGFB VEGFA RPE65 PLG PGF CRYAA
19 central retinal artery occlusion 30.6 VEGFA PLG CRYAA
20 retinal ischemia 30.5 VEGFA PGF KDR CRYAA
21 macular degeneration, age-related, 7 30.5 RPE65 HTRA1
22 degenerative myopia 30.5 VEGFB VEGFA PGF CFH ARMS2
23 keratitis, hereditary 30.4 VEGFC VEGFA CRYAA
24 central retinal vein occlusion 30.4 VEGFB VEGFA PLG PGF KDR FLT1
25 diabetic macular edema 30.3 VEGFC VEGFB VEGFA TEK PTPRB PGF
26 retinal vascular disease 30.3 VEGFB VEGFA TEK RPE65 PLG PGF
27 retinal vascular occlusion 30.3 VEGFB VEGFA PLG PGF KDR FLT1
28 choroiditis 30.1 VEGFA RPE65 HTRA1 CFH CFB ARMS2
29 retinal artery occlusion 30.0 VEGFB VEGFA PLG PGF KDR FLT1
30 myocardial infarction 29.7 VEGFA TEK PLG PGF KDR FLT1
31 neovascular glaucoma 29.5 VEGFD VEGFC VEGFB VEGFA PLG PGF
32 eye disease 29.1 VEGFC VEGFB VEGFA TEK RPE65 PLG
33 exudative vitreoretinopathy 1 28.5 VLDLR VEGFD VEGFC VEGFB VEGFA TEK
34 macular degeneration, age-related, 1 27.7 VLDLR VEGFD VEGFC VEGFB VEGFA TEK
35 anterior uveitis 11.0
36 rhabdomyosarcoma 2 10.9
37 periodontal ehlers-danlos syndrome 10.8
38 cataract 10.8
39 twin-reversed arterial perfusion sequence 10.8
40 fibrosis of extraocular muscles, congenital, 1 10.8
41 hawkinsinuria 10.7
42 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 10.7
43 47 xxx syndrome 10.7
44 ataxia with vitamin e deficiency 10.7
45 macular degeneration, age-related, 12 10.7
46 macular dystrophy, dominant cystoid 10.7
47 neurodegeneration with brain iron accumulation 2a 10.7
48 uveitis 10.7
49 reading disorder 10.7
50 familial hyperlipidemia 10.6

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ANGPT2 CFB CFH COL18A1 FLT1 KDR
2 growth/size/body region MP:0005378 10.07 CFB CFH FLT1 HTRA1 KDR PGF
3 cardiovascular system MP:0005385 10.06 ANGPT2 CFB CFH COL18A1 FLT1 HTRA1
4 immune system MP:0005387 9.73 ANGPT2 CFB CFH FLT1 KDR PGF
5 vision/eye MP:0005391 9.47 ANGPT2 CFH COL18A1 CRYAA FLT1 HTRA1

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
2
Ranibizumab Approved Phase 4 347396-82-1
3
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020
4
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
5
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
6
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Verteporfin Approved, Investigational Phase 4 129497-78-5 5362420
16
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
17 Cathartics Phase 4
18 Carboxymethylcellulose Sodium Phase 4
19 Laxatives Phase 4
20 Angiogenesis Inhibitors Phase 4
21 Pharmaceutical Solutions Phase 4
22 Ophthalmic Solutions Phase 4
23 Antirheumatic Agents Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Anti-Inflammatory Agents Phase 4
27 Analgesics Phase 4
28 Omega 3 Fatty Acid Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Pyranoprofen Phase 4
31 Tocolytic Agents Phase 4
32 Gastrointestinal Agents Phase 4
33 Antineoplastic Agents, Hormonal Phase 4
34 Antiemetics Phase 4
35
Methylprednisolone Acetate Phase 4 584547
36 BB 1101 Phase 4
37 Neuroprotective Agents Phase 4
38 Immunologic Factors Phase 4
39 glucocorticoids Phase 4
40 Hormones Phase 4
41 Hormone Antagonists Phase 4
42 Immunosuppressive Agents Phase 4
43
Triamcinolone hexacetonide Phase 4
44
Triamcinolone diacetate Phase 4
45
Triamcinolone Acetonide Phase 4 6436
46 Dermatologic Agents Phase 4
47 Photosensitizing Agents Phase 4
48
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 5284549
49
Timolol Approved Phase 2, Phase 3 26839-75-8 5478 33624
50
Plasminogen Approved Phase 3 9001-91-6

Interventional clinical trials:

(show top 50) (show all 403)
# Name Status NCT ID Phase Drugs
1 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Unknown status NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
2 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Unknown status NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
3 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
4 A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
5 Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab
6 A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus "Pro Re Nata" Regimen of Conbercept in Neovascular Age-related Macular Degeneration Unknown status NCT02802657 Phase 4 Conbercept
7 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
8 Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy Unknown status NCT02976194 Phase 4 ranibizumab
9 Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) Unknown status NCT01961414 Phase 4 Aflibercept
10 Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations Unknown status NCT01213667 Phase 4 Ranibizumab
11 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD Completed NCT02246829 Phase 4
12 A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
13 A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg. Completed NCT02161575 Phase 4 Ranibizumab
14 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
15 A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study). Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
16 A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD) Completed NCT01775124 Phase 4 Ranibizumab
17 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
18 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Completed NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
19 LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
20 Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study Completed NCT02944227 Phase 4 Lucentis
21 Single or Combined Protocols for the Treatment of Patients With Neovascular Age-related Macular Degeneration: Compliance, Risk/Benefit and Cost/Benefit Ratios Completed NCT03552770 Phase 4 Bevacizumab
22 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
23 A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
24 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
25 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
26 A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients Completed NCT01988662 Phase 4
27 Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Completed NCT01896284 Phase 4 0.5mg aflibercept
28 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
29 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
30 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration Completed NCT02125864 Phase 4
31 FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
32 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
33 A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration Completed NCT01810042 Phase 4 ranibizumab
34 Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
35 A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
36 Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy Completed NCT00331435 Phase 4
37 Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
38 Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
39 A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study) Completed NCT01617148 Phase 4 Aflibercept
40 A Phase IV, Multicenter, Open-Label, Single-Arm Study Of The Response to Treatment After Transition to The Port Delivery System With Ranibizumab [Susvimo (Ranibizumab Injection)] In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab Recruiting NCT04853251 Phase 4 LUCENTIS (ranibizumab injection)
41 One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study Recruiting NCT04774926 Phase 4 Brolucizumab
42 A Real-world, Prospective, Multi-center, Open-label, Phase IV Clinical Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Recruiting NCT05269966 Phase 4
43 A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study Recruiting NCT04597632 Phase 4 brolucizumab
44 Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections Recruiting NCT04563299 Phase 4 Dextenza 0.4Mg Ophthalmic Insert;Prednisolone Acetate
45 Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study. Recruiting NCT05093374 Phase 4 anti-VEGF agent
46 A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration Recruiting NCT04679935 Phase 4
47 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Recruiting NCT02681783 Phase 4 aflibercept
48 OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy Not yet recruiting NCT04075136 Phase 4 Ranibizumab;Triamcinolone Acetonide;verteporfin
49 Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept Terminated NCT04287348 Phase 4 Brolucizumab 6 mg solution for intravitreal injection
50 A Single-center, Open Label, Prospective Study Assessing the IOP (Intraocular Pressure) Patterns Using SENSIMED Triggerfish® in Association With Anti-VEGF Injection Terminated NCT01983579 Phase 4

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

Organs/tissues related to Kuhnt-Junius Degeneration:

MalaCards : Eye, Retina, Endothelial, Bone Marrow, Bone, Whole Blood, Monocytes

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

(show top 50) (show all 3681)
# Title Authors PMID Year
1
Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles. 62
34083208 2022
2
What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register. 62
35064747 2022
3
One-year outcome of neovascular age-related macular degeneration patients followed-up using different optical coherence tomography modalities. 62
35285308 2022
4
RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: A Meta-analysis. 62
36269802 2022
5
The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. 62
34750590 2022
6
Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. 62
34039560 2022
7
Genetic associations of central serous chorioretinopathy: a systematic review and meta-analysis. 62
34039561 2022
8
Suppression of myeloid PFKFB3-driven glycolysis protects mice from choroidal neovascularization. 62
35830274 2022
9
Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis. 62
35970234 2022
10
Masking of macular neovascular membranes by subretinal hyperreflective material on optical coherence tomography angiography. 62
35243925 2022
11
Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic. 62
36254407 2022
12
Evaluation of an Artificial Intelligence-based Detector of Sub- and Intra-Retinal Fluid on a large set of OCT volumes in AMD and DME. 62
36215958 2022
13
MULTIMODAL IMAGING CHARACTERISTICS AND FUNCTIONAL CORRELATES IN RIP HEALING. 62
35976222 2022
14
nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey. 62
35552499 2022
15
[Retinal vein occlusion : Intravitreal pharmacotherapies and treatment strategies for the management of macular edema]. 62
36239802 2022
16
Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring: The ALOFT Study. 62
35483614 2022
17
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel. 62
36207506 2022
18
Macular thickness fluctuation in neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor. 62
34283969 2022
19
Interleukin levels in neovascular age-related macular degeneration: evaluation of morphological and functional progression over 5 years. 62
35412079 2022
20
Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. 62
36228779 2022
21
Optical coherence tomography and OCT angiography characteristics of indocyanine green angiographic plaques in nonexudative age-related macular degeneration. 62
36201752 2022
22
Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration. 62
36239676 2022
23
Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study. 62
36258240 2022
24
Risk factors and clinical significance of prechoroidal cleft in eyes with neovascular age-related macular degeneration in Caucasian patients. 62
36259092 2022
25
Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration. 62
35989065 2022
26
The Need for Treatment of Neovascular Age-Related Macular Degeneration: A Study Based on the Polish National Registry. 62
35871711 2022
27
Novel metrics for evaluating decision making in a 'Treat and Extend' regimen for neovascular age related macular degeneration. 62
34642497 2022
28
PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration. 62
35511286 2022
29
Development of subretinal hemorrhage after treatment discontinuation for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. 62
35612614 2022
30
Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United States. 62
35738393 2022
31
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis. 62
35821380 2022
32
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration. 62
35759124 2022
33
Update on the utility of en face optical coherence tomography in the assessment of vitreoretinal diseases. 62
36266145 2022
34
Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan - Results from the 12-month, observational RENOWNED study. 62
35279311 2022
35
Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. 62
34385697 2022
36
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. 62
35405352 2022
37
Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab. 62
35427803 2022
38
NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY AFTER INTRAVITREAL AFLIBERCEPT FOR AGE-RELATED MACULAR DEGENERATION. 62
32969978 2022
39
Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center. 62
34761684 2022
40
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. 62
35537533 2022
41
Objective evaluation of changes in lens clarity after repeated injections of ranibizumab in patients with neovascular age-related macular degeneration. 62
35445877 2022
42
Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. 62
36104522 2022
43
Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. 62
36127425 2022
44
Review of fibrosis in neovascular age-related macular degeneration. 62
36162537 2022
45
Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study. 62
36123657 2022
46
Personalized Approach in Treatment of Neovascular Age-Related Macular Degeneration. 62
36143241 2022
47
Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes. 62
35381391 2022
48
Comparison of treatment methods for submacular hemorrhage in neovascular age-related macular degeneration: conservative versus active surgical strategy. 62
36050401 2022
49
Sub-retinal pigment epithelium tubules in non-neovascular age-related macular degeneration. 62
36071082 2022
50
Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. 62
36117281 2022

Variations for Kuhnt-Junius Degeneration

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

Pathways related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 ANGPT2 COL18A1 FLT1 KDR PGF TEK
2 13.75 FLT1 KDR PGF PLG TEK VEGFA
3
Show member pathways
13.67 VEGFD VEGFC VEGFB VEGFA TEK PGF
4
Show member pathways
13.54 VEGFD VEGFC VEGFB TEK PTPRB PGF
5
Show member pathways
13.51 VEGFD VEGFC VEGFB VEGFA TEK PGF
6
Show member pathways
13.39 VEGFD VEGFC VEGFB TEK PGF KDR
7
Show member pathways
13.3 VEGFD VEGFC VEGFB TEK PGF KDR
8
Show member pathways
13.28 VEGFD VEGFC VEGFB TEK PTPRB PGF
9
Show member pathways
13.27 ANGPT2 PLG TEK VEGFA VEGFB VEGFC
10
Show member pathways
13.26 FLT1 KDR PGF TEK VEGFA VEGFB
11
Show member pathways
13.05 VEGFD VEGFC VEGFB PGF KDR FLT1
12
Show member pathways
13.03 VEGFD VEGFC VEGFB PGF KDR FLT1
13
Show member pathways
12.86 VEGFD VEGFC VEGFB VEGFA TEK PGF
14 12.78 FLT1 KDR PGF PLG VEGFA VEGFB
15
Show member pathways
12.69 VEGFD VEGFC VEGFB PGF KDR FLT1
16
Show member pathways
12.62 VEGFD VEGFC VEGFB PGF KDR FLT1
17
Show member pathways
12.41 VEGFD VEGFC VEGFB VEGFA PGF KDR
18
Show member pathways
12.37 VEGFD VEGFC VEGFB VEGFA KDR FLT1
19
Show member pathways
12.35 VEGFD VEGFC VEGFB TEK PGF KDR
20
Show member pathways
12.23 VEGFD VEGFC VEGFB VEGFA PGF KDR
21
Show member pathways
12.22 VEGFC VEGFB VEGFA KDR FLT1
22 12.22 VEGFD VEGFC VEGFB VEGFA TEK PGF
23 12.1 VEGFD VEGFC VEGFB VEGFA PGF KDR
24 12.08 VEGFC VEGFB TEK KDR FLT1 ANGPT2
25
Show member pathways
11.83 TEK KDR FLT1
26 11.79 VEGFA KDR FLT1
27 11.69 VEGFD VEGFC VEGFB PGF
28 11.65 VEGFA KDR FLT1
29 11.61 VEGFD VEGFC VEGFB VEGFA
30 11.58 VEGFC VEGFB TEK KDR FLT1 ANGPT2
31 11.57 VEGFA TEK KDR
32 11.56 VEGFA KDR FLT1
33 11.52 VEGFA PLG KDR
34 11.49 VEGFC VEGFB VEGFA
35 11.47 VEGFB VEGFA KDR FLT1
36 11.29 FLT1 KDR VEGFA
37 11.19 VEGFD VEGFC VEGFA
38 11.19 VEGFB VEGFA PGF FLT1
39 11.05 TEK KDR FLT1
40 10.98 VEGFA FLT1
41 10.88 ANGPT2 COL18A1 FLT1 KDR PGF TEK
42 10.87 VEGFA FLT1
43 10.84 VEGFA KDR
44
Show member pathways
10.7 VEGFC VEGFB VEGFA
45 10.63 FLT1 KDR TEK
46 10.45 VEGFA KDR
47
Show member pathways
10.37 VEGFD VEGFC VEGFB VEGFA PGF KDR
48 10.35 VEGFA KDR

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.12 ANGPT2 CFB CFH CFHR2 COL18A1 FLT1
2 receptor complex GO:0043235 9.96 VLDLR TEK PTPRB KDR FLT1
3 platelet alpha granule lumen GO:0031093 9.85 VEGFD VEGFC VEGFB VEGFA PLG
4 extracellular space GO:0005615 9.75 ANGPT2 CFB CFH CFHR2 COL18A1 FLT1

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.35 VEGFD VEGFC VEGFB VEGFA PGF KDR
2 positive regulation of protein phosphorylation GO:0001934 10.34 VEGFD VEGFC VEGFB VEGFA TEK PGF
3 response to hypoxia GO:0001666 10.29 ANGPT2 PGF VEGFA VEGFB VEGFC VEGFD
4 positive regulation of endothelial cell proliferation GO:0001938 10.25 KDR PGF TEK VEGFA VEGFB VEGFC
5 angiogenesis GO:0001525 10.25 ANGPT2 COL18A1 FLT1 KDR PGF PTPRB
6 cell differentiation GO:0030154 10.23 VEGFD VEGFC VEGFA PGF KDR FLT1
7 positive regulation of angiogenesis GO:0045766 10.21 VEGFD VEGFC VEGFB VEGFA TEK PGF
8 positive regulation of cell division GO:0051781 10.18 PGF VEGFA VEGFB VEGFC VEGFD
9 positive regulation of MAPK cascade GO:0043410 10.17 VEGFA TEK KDR FLT1
10 positive chemotaxis GO:0050918 10.16 VEGFD VEGFC VEGFB VEGFA PGF
11 sprouting angiogenesis GO:0002040 10.15 VEGFD VEGFC VEGFB VEGFA TEK PGF
12 induction of positive chemotaxis GO:0050930 10.13 VEGFD VEGFC VEGFB VEGFA PGF
13 positive regulation of blood vessel endothelial cell migration GO:0043536 10.09 VEGFC VEGFA KDR
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.09 VEGFA TEK KDR FLT1
15 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.05 VEGFA KDR FLT1
16 complement activation GO:0006956 10.04 CFHR2 CFH CFB
17 positive regulation of focal adhesion assembly GO:0051894 10.03 KDR TEK VEGFA
18 positive regulation of epithelial cell proliferation GO:0050679 10 VEGFC VEGFA KDR HTRA1
19 vascular wound healing GO:0061042 9.92 VEGFA KDR
20 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.91 KDR VEGFA
21 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.9 KDR VEGFA
22 glomerulus vasculature development GO:0072012 9.89 TEK ANGPT2
23 Tie signaling pathway GO:0048014 9.88 TEK ANGPT2
24 positive regulation of mast cell chemotaxis GO:0060754 9.85 PGF VEGFA VEGFB VEGFC VEGFD
25 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.8 VEGFD VEGFC VEGFB VEGFA PGF KDR
26 vascular endothelial growth factor signaling pathway GO:0038084 9.47 VEGFD VEGFC VEGFB VEGFA PGF KDR

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.4 VEGFD VEGFB VEGFA TEK PGF KDR
2 heparin binding GO:0008201 10.1 VEGFB VEGFA PGF CFH
3 growth factor activity GO:0008083 9.96 VEGFD VEGFC VEGFB VEGFA PGF
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.95 TEK KDR FLT1
5 growth factor binding GO:0019838 9.91 FLT1 HTRA1 KDR
6 vascular endothelial growth factor receptor activity GO:0005021 9.76 KDR FLT1
7 vascular endothelial growth factor receptor 1 binding GO:0043183 9.67 VEGFA VEGFB
8 chemoattractant activity GO:0042056 9.65 VEGFD VEGFC VEGFB VEGFA PGF
9 receptor ligand activity GO:0048018 9.63 PGF VEGFA VEGFB VEGFC VEGFD
10 vascular endothelial growth factor receptor 3 binding GO:0043185 9.62 VEGFD VEGFC
11 vascular endothelial growth factor receptor binding GO:0005172 9.32 VEGFD VEGFC VEGFB VEGFA PGF

Sources for Kuhnt-Junius Degeneration

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....